Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bariatric surgery cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (98 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 14 | 489 | 28% |
| 2020 | 2 | 357 | 30% |
| 2021 | 5 | 339 | 32% |
Gastric bypass, sleeve gastrectomy, gastric banding: mostly patients under 65. Professional codes (what the surgeon bills): CPT 43644, 43775, 43770; the hospital bills MS-DRG 619, 620, 621.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 0 | 318−18%/yr | −18%/yr | 0.2 | 0% | 200 in 2030−7.2%/yr |
| Pennsylvania | 0 | 197 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 66 | 5,037−2.7%/yr | −2.7%/yr | 5.60.9× | 1% | 5,860 in 2030+2.6%/yr |
| Cholecystectomy & appendectomy |
Bariatric surgery in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
| 2024 |
| 230 |
| 39% |
| 2025 est. | ≈ 180 | – |
| 2026 est. | ≈ 180 | – |
| 2022 | 5 | 352 | 35% |
| 2023 | 2 | 277 | 38% |
| 2024 | 0 | 230 | 39% |
| 2025 from claims | – | 177 143–208 | 40% |
| 2026 forecast | – | 183 143–229 | 39% |
| 2027 forecast | – | 186 138–245 | 40% |
| 2028 forecast | – | 188 133–260 | 40% |
| 2029 forecast | – | 191 130–275 | 40% |
| 2030 forecast | – | 194 127–289 | 40% |
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| −22%/yr |
| 0.1 |
| 0% |
| 190 in 2030−0.9%/yr |
| New Jersey | 0 | 168−20%/yr | −20%/yr | 0.2 | 0% | 120 in 2030−5%/yr |
| New Hampshire | 0 | 103−3.3%/yr | −3.3%/yr | 0.4 | 0% | 90 in 2030−2.3%/yr |
| 60 |
| 3,162−3.7%/yr |
| −3.7%/yr |
| 3.40.9× |
| 0% |
| 3,520 in 2030+1.8%/yr |
| Colorectal resection | 10 | 1,485−3.1%/yr | −3.1%/yr | 1.61.0× | 0% | 1,660 in 2030+1.9%/yr |
| Antireflux & hiatal hernia surgery | 8 | 640+1.2%/yr | +1.2%/yr | 0.71.1× | 0% | 1,240 in 2030+12%/yr |
| Breast reconstruction | 1 | 327−2.7%/yr | −2.7%/yr | 0.30.8× | 0% | 340 in 2030+0.7%/yr |
No metro breakdown yet.
Medtronic leads with 84% of company spending on these surgeons in 2025, +10 pts on 2024.
In 2025, 3 companies reported engagement with Massachusetts’s surgeons worth $18K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.